Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.

Background: Ovulation induction by human menopausal gonadotrophin (HMG) results in temporal luteal phase defect. Luteal support therapies are required to support embryo implantation in stimulated cycle especially in luteal phase defect infertile women.  Objective: The objective of the present study...

Full description

Bibliographic Details
Main Authors: Mundhir T. Ridhaa, Saeeda A. AL-Anssari, Zuher Kanan, Ahmed K. Allow, Sarmed S. Khounda
Format: Article
Language:English
Published: College of Medicine University of Baghdad 2007-04-01
Series:مجلة كلية الطب
Subjects:
Online Access:http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1425
_version_ 1797332907520425984
author Mundhir T. Ridhaa
Saeeda A. AL-Anssari
Zuher Kanan
Ahmed K. Allow
Sarmed S. Khounda
author_facet Mundhir T. Ridhaa
Saeeda A. AL-Anssari
Zuher Kanan
Ahmed K. Allow
Sarmed S. Khounda
author_sort Mundhir T. Ridhaa
collection DOAJ
description Background: Ovulation induction by human menopausal gonadotrophin (HMG) results in temporal luteal phase defect. Luteal support therapies are required to support embryo implantation in stimulated cycle especially in luteal phase defect infertile women.  Objective: The objective of the present study was to investigate the clinical significance of progesterone, aspirin and HCG on human embryo implantation in women with luteal phase defect following ICSI and embryo transfer (ET). Patients and Methods: The female patients were divided into six groups depending on the type of the luteal support protocols (LSP). Group 1 (No= 54), received 10 mg oral progesterone (P), group 2 (No= 35) received P plus HCG, group 3 (No= 59) received P plus HCG plus oral aspirin, group 4 (No= 47) received vaginal P administered 24 hours before embryo transfer plus oral aspirin, group 5 (No= 40)  received vaginal P administered 12 hours after embryo transfer plus oral aspirin and group 6 (No= 46) received intramuscular P plus oral aspirin. The LSP were continued for at least 12 weeks, when the BHCG test was positive, (tested two weeks after embryo transfer). Results: Statistical analysis of the clinical data showed no significant differences between the LSP in regard to patient's age, body mass index (B/M2), basal FSH/LH ratio and estradiol concentration at the day of HCG injection. The ICSI rate, percentages of embryos developed in vitro, and the numbers of the transferable quality embryos were similar in all groups (P>0.05). The pregnancy rate was significantly higher (P < 0.05), in group 4 compared to other groups (38.66% versus 24.51%(G 1), 22.53% (G 2), 28.66% (G 3), 25% (G 5), 21.60% (G 6). The percentages of viable fetal sac development per patient were 31.49 (17/54), in G 1, 42.86 (15/35), in G 2, 49.16 (29/59), in G 3, 59.58 (28/47), in G 4, 32.50 (13/40), in G 5, and 34.79 (16/46), G 6. The percent of viable gestation sac was significantly higher in group 4 compared to other groups (P < 0.05). Concl u s i o n s : The administration of 400 mg /day vaginal progesterone 24 hours before ET and 100 mg/day aspirin five days after ET results in significant improvements in pregnancy and embryo implantation rates and development of viable fetuses in luteal phase defect infertile women undergoing ICSI-ET.
first_indexed 2024-03-08T07:56:11Z
format Article
id doaj.art-ce008286e80e434c865255f1af01493e
institution Directory Open Access Journal
issn 0041-9419
2410-8057
language English
last_indexed 2024-03-08T07:56:11Z
publishDate 2007-04-01
publisher College of Medicine University of Baghdad
record_format Article
series مجلة كلية الطب
spelling doaj.art-ce008286e80e434c865255f1af01493e2024-02-02T13:51:57ZengCollege of Medicine University of Baghdadمجلة كلية الطب0041-94192410-80572007-04-01491Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.Mundhir T. Ridhaa0Saeeda A. AL-Anssari1Zuher Kanan2Ahmed K. Allow3Sarmed S. Khounda4Texas A&M University, College Station, TX 77843-4466 USA Part of this study was presented as an abstract in 12TH Annual Scientific Meeting of Texas Forum on Reproductive Sciences, Texas A & M University System Medical Sciences Center, Houston, Texas, USA, 2006Baghdad Teaching Hospital, College of Medicine, Baghdad University, IraqBaghdad Teaching Hospital, College of Medicine, Baghdad University, IraqIVF Institute For Embryo Research and Infertility1 and Department of Obstetric and Gynecology and Physiology DepartmentBaghdad Teaching Hospital, College of Medicine, Baghdad University, IraqBackground: Ovulation induction by human menopausal gonadotrophin (HMG) results in temporal luteal phase defect. Luteal support therapies are required to support embryo implantation in stimulated cycle especially in luteal phase defect infertile women.  Objective: The objective of the present study was to investigate the clinical significance of progesterone, aspirin and HCG on human embryo implantation in women with luteal phase defect following ICSI and embryo transfer (ET). Patients and Methods: The female patients were divided into six groups depending on the type of the luteal support protocols (LSP). Group 1 (No= 54), received 10 mg oral progesterone (P), group 2 (No= 35) received P plus HCG, group 3 (No= 59) received P plus HCG plus oral aspirin, group 4 (No= 47) received vaginal P administered 24 hours before embryo transfer plus oral aspirin, group 5 (No= 40)  received vaginal P administered 12 hours after embryo transfer plus oral aspirin and group 6 (No= 46) received intramuscular P plus oral aspirin. The LSP were continued for at least 12 weeks, when the BHCG test was positive, (tested two weeks after embryo transfer). Results: Statistical analysis of the clinical data showed no significant differences between the LSP in regard to patient's age, body mass index (B/M2), basal FSH/LH ratio and estradiol concentration at the day of HCG injection. The ICSI rate, percentages of embryos developed in vitro, and the numbers of the transferable quality embryos were similar in all groups (P>0.05). The pregnancy rate was significantly higher (P < 0.05), in group 4 compared to other groups (38.66% versus 24.51%(G 1), 22.53% (G 2), 28.66% (G 3), 25% (G 5), 21.60% (G 6). The percentages of viable fetal sac development per patient were 31.49 (17/54), in G 1, 42.86 (15/35), in G 2, 49.16 (29/59), in G 3, 59.58 (28/47), in G 4, 32.50 (13/40), in G 5, and 34.79 (16/46), G 6. The percent of viable gestation sac was significantly higher in group 4 compared to other groups (P < 0.05). Concl u s i o n s : The administration of 400 mg /day vaginal progesterone 24 hours before ET and 100 mg/day aspirin five days after ET results in significant improvements in pregnancy and embryo implantation rates and development of viable fetuses in luteal phase defect infertile women undergoing ICSI-ET.http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1425Embryo Implantation, ICSI-ET, Vaginal Progesterone and Aspirin Therapies
spellingShingle Mundhir T. Ridhaa
Saeeda A. AL-Anssari
Zuher Kanan
Ahmed K. Allow
Sarmed S. Khounda
Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.
مجلة كلية الطب
Embryo Implantation, ICSI-ET, Vaginal Progesterone and Aspirin Therapies
title Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.
title_full Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.
title_fullStr Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.
title_full_unstemmed Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.
title_short Progesterone Therapy Administered 24 hours Before Embryo Transfer in ICSI Cycle Improves Embryo Implantation and Pregnancy in Women With Luteal Phase Defect.
title_sort progesterone therapy administered 24 hours before embryo transfer in icsi cycle improves embryo implantation and pregnancy in women with luteal phase defect
topic Embryo Implantation, ICSI-ET, Vaginal Progesterone and Aspirin Therapies
url http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1425
work_keys_str_mv AT mundhirtridhaa progesteronetherapyadministered24hoursbeforeembryotransferinicsicycleimprovesembryoimplantationandpregnancyinwomenwithlutealphasedefect
AT saeedaaalanssari progesteronetherapyadministered24hoursbeforeembryotransferinicsicycleimprovesembryoimplantationandpregnancyinwomenwithlutealphasedefect
AT zuherkanan progesteronetherapyadministered24hoursbeforeembryotransferinicsicycleimprovesembryoimplantationandpregnancyinwomenwithlutealphasedefect
AT ahmedkallow progesteronetherapyadministered24hoursbeforeembryotransferinicsicycleimprovesembryoimplantationandpregnancyinwomenwithlutealphasedefect
AT sarmedskhounda progesteronetherapyadministered24hoursbeforeembryotransferinicsicycleimprovesembryoimplantationandpregnancyinwomenwithlutealphasedefect